AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18759644
Drug: Aripiprazole (APZ)
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole (APZ) at a mean dose of 6.7 mg/day
Trial: 12679354
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) 6 mg/day
Trial: 12679354
Drug: discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: discontinuation of rhGH therapy
Trial: 8960947
Drug: Fish oils
RxNorm normalized name: fish oils
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oils (12 capsules, 3.6 g/day of omega 3)
Trial: 8960947
Drug: Soya oil
RxNorm normalized name: Soya oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soya oil (12 capsules per day)
Trial: 6622502
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg theophylline tablet taken as 2 halves
Trial: 6622502
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg theophylline tablet taken whole
Trial: 31831255
Drug: B-cell activating
RxNorm normalized name: B-cell activating factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-cell activating factor receptor (Ianalumab) inhibition
Trial: 31831255
Drug: Lymphotoxin beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphotoxin beta receptor (baminercept)
Trial: 31831255
Drug: Other kinase
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other kinase inhibitors
Trial: 31831255
Drug: Transmembrane activator
RxNorm normalized name: Human Transmembrane Activator and CAML Interactor (TACI) Immunoglobulin G1 Fc Domain Fusion Protein (Fc5)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmembrane activator and calcium-modulator and cytophilin ligand interactor TACI fusion protein (RC18)
Trial: 31831255
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose recombinant interleukin-2 to expand T-regulatory cells
Trial: 30870970
Drug: Watermelon (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watermelon (2 cups daily)
Trial: 12174061
Drug: Graftskin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graftskin therapy with aggressive debridement and standardized wound care
Trial: 9714263
Drug: Venlafaxine, 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine, 37.5 mg twice daily (increased to 75 mg twice daily after 3 weeks if poor response)
Trial: 9714263
Drug: Fluoxetine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine, 20 mg once daily (increased to 20 mg twice daily after 3 weeks if poor response)
Trial: 2617209
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of amoxycillin
Trial: 2617209
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of amoxycillin combined with 1 g of probenecid
Trial: 28670249
Drug: Training program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training program based on the Precede model, conducted during four sessions twice a week for one hour.
Trial: 21768737
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein (SP) formula containing 12 g of SP, given for 20 weeks
Trial: 19537839
Drug: Lubiprostone 8
RxNorm normalized name: LUBIPROSTONE 8MCG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone 8 microg twice daily for 3 months
Trial: 19537839
Drug: Lubiprostone 8
RxNorm normalized name: LUBIPROSTONE 8MCG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone 8 microg twice daily
Trial: 16414215
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day isoflavone supplement (n=15)
Trial: 16414215
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo capsules (n=14)
Trial: 8808491
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg ascorbate per day for 4 weeks
Trial: 1393763
Drug: Azelastine, 0.28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine, 0.28 mg to each nostril
Trial: 25412225
Drug: IV antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV antibiotics
Trial: 31373271
Drug: PO antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO antibiotics
Trial: 12131220
Drug: Pneumococcal conjugate
RxNorm normalized name: pneumococcal conjugate PCV 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal conjugate vaccine (one or two doses)
Trial: 12131220
Drug: Polysaccharide vaccine
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysaccharide vaccine (one dose)
Trial: 12131220
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pneumococcal conjugate and polysaccharide vaccines (one dose of each)
Trial: 9607049
Drug: Injection in
RxNorm normalized name: Emend Injection Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection in the buttock
Trial: 9607049
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of OPV and/or HBV
Trial: 7618425
Drug: i.v. ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketorolac tromethamine 30 mg
Trial: 2151275
Drug: Zoladex plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex plus flutamide (Zoladex 3.6 mg every 4 weeks, flutamide 250 mg t.i.d.)
Trial: 23340533
Drug: Quinidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (50 mg)
Trial: 19059635
Drug: Whole-body hyperthermia
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body hyperthermia (WBH) in combination with carboplatin
Trial: 16919060
Drug: Intensive advice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive advice to withdraw the overused medication (Group A)
Trial: 16919060
Drug: Standard out‐patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard out‐patient detoxification programme (advice+prednisone+preventive treatment) (Group B)
Trial: 11164700
Drug: Rufinamide (400-1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufinamide (400-1600 mg/day)
Trial: 9245470
Drug: Compound cue
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound cue model
Trial: 2826550
Drug: IV enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV enalaprilat 1.25 mg q6h for 24 hours, increased to 5 mg q6h for nonresponding patients
Trial: 29562147
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication therapy with antibiotics
Trial: 25403867
Drug: Chia flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chia flour (35 g/day) for 12 weeks
Trial: 11934185
Drug: 1 percent
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 percent penciclovir cream
Trial: 10860034
Drug: Tetracycline fiber
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline fiber therapy
Trial: 1973351
Drug: Social Skills
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Skills Training (SST) - 25 twice a week 90-min group sessions
Trial: 1973351
Drug: Group Exposure
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Exposure (GE) - 4 weekly sessions (8-hr total, including 2 hr discussion)
Trial: 1973351
Drug: Individual Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Exposure (IE) - 4 weekly sessions (3 hr total, including 1 hr discussion)
Trial: 504040
Drug: Tienilic acid
RxNorm normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tienilic acid 250 mg
Trial: 28812321
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg daily (Group B)
Trial: 28812321
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg daily (Group A)
Trial: 26596056
Drug: Dabigatran (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (110 mg b.i.d)
Trial: 26596056
Drug: Apixaban (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (5 mg b.i.d)
Trial: 19747876
Drug: Dexamethasone-based protocol
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone-based protocol (DCOG ALL-9) for NHR patients: three-drug induction (dexamethasone, vincristine, asparaginase) for 6 weeks, medium-dose methotrexate for 3 weeks, maintenance therapy until 109 weeks.
Trial: 19747876
Drug: Dexamethasone-based protocol
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone-based protocol (DCOG ALL-9) for HR patients: four-drug induction (as for NHR plus daunorubicin) for 6 weeks, high-dose methotrexate for 8 weeks, maintenance therapy until 109 weeks.
Trial: 11455770
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms PGE1 + 15 mg papaverine hydrochloride + 0.5 mg phentolamine (trimix)
Trial: 11455770
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg papaverine hydrochloride + 1 mg phentolamine (bimix)
Trial: 28526536
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine (3·6 mg/kg intravenously every 3 weeks)
Trial: 28526536
Drug: Capecitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1000 mg/m2 orally twice daily on days 1‐14 of each 21-day cycle) plus Lapatinib (1250 mg orally once daily on days 1‐21)
Trial: 12940872
Drug: Sibutramine, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine, 10 mg once daily
Trial: 11885173
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed in the study
Trial: 11885173
Drug: Stratified analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified analysis of data up to 72 months after implant uncovering
Trial: 8833025
Drug: Theoretically based,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theoretically based, structured experimental treatment program
Trial: 1467099
Drug: Alfentanil loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil loading dose of 85 micrograms kg‐1 and infusion of 65 micrograms kg‐1 h‐1
Trial: 1467099
Drug: Alfentanil loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil loading dose of 65 micrograms kg‐1 and infusion of 50 micrograms kg‐1 h‐1
Trial: 6205337
Drug: Cis-dichlorodiammineplatinum(II) (cis-DDP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cis-dichlorodiammineplatinum(II) (cis-DDP) 33 mg/kg i.v. day 1 and Bleomycin (BLM) 15 mg/m2 i.v. continuously day 2-6 (arm A)
Trial: 6205337
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 30 mg/m2 i.v. day 1 + 6 and Vindesine (VDS) 3 mg/m2 day 2 + 7 (arm B)
Trial: 6205337
Drug: Chemotherapy (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (both arms combined)
Trial: 29659797
Drug: Apixaban (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (5 mg b.i.d., reduced to 2.5 mg b.i.d. if applicable)
Trial: 29659797
Drug: Heparin/Vitamin K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin/Vitamin K Antagonist (VKA)
Trial: 15643230
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg Serenoa repens (SR) orally twice daily for 3 months
Trial: 15643230
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment for 3 weeks before surgery)
Trial: 9272316
Drug: Ciprofloxacin ophthalmic
RxNorm normalized name: ciprofloxacin ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin ophthalmic solution (0.3%)
Trial: 8997576
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid gel (1%)
Trial: 1360665
Drug: recombinant gp160
RxNorm normalized name: Recombinant gp160 vaccine
DrugBank: VaxSyn (DB17827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant gp160 vaccine
Trial: 1360665
Drug: recombinant hepatitis
RxNorm normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant hepatitis B vaccine (control)
Trial: 6142907
Drug: Alprazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (2 to 6 mg/day)
Trial: 6142907
Drug: Ibuprofen (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (0.8 to 2.4 g/day)
Trial: 6142907
Drug: Alprazolam (6.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (6.3 mg/day after crossover)
Trial: 29480087
Drug: Running and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Running and brisk walking for 30‐45 min twice a week (IND)
Trial: 29480087
Drug: Running and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Running and brisk walking for 30‐45 min twice a week (GR)
Trial: 25560349
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera gel dressing
Trial: 23103771
Drug: Internet-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based therapy (IT)
Trial: 16166192
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 500-3000 mg/day
Trial: 17644828
Drug: Benzodiazepine discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine discontinuation programme with group psychotherapy
Trial: 17644828
Drug: Benzodiazepine discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine discontinuation programme without psychotherapy
Trial: 17644828
Drug: Complete discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete discontinuation of benzodiazepines
Trial: 15859929
Drug: BT563 (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT563 (monoclonal antibody against interleukin-2 receptor) for 10 days in kidney transplant recipients
Trial: 15859929
Drug: BT563 (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT563 (monoclonal antibody against interleukin-2 receptor) for 7 days in heart transplant recipients
Trial: 12190808
Drug: Interscalene brachial
RxNorm normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene brachial plexus block (ISB) with 15 ml of ropivacaine (5 mg/ml)
Trial: 12190808
Drug: Subacromial bursa
RxNorm normalized name: Capsella bursa-pastoris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial bursa block (SUB) with 15 ml of ropivacaine (5 mg/ml)
Trial: 12190808
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) with 15 ml of 0.9% saline
Trial: 2534373
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of ipratropium bromide (IPB) followed by 5 mg of salbutamol sulfate (SAS)
Trial: 2534373
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of salbutamol sulfate (SAS)
Trial: 2534373
Drug: Sequential inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential inhaled SAS after IPB
Trial: 2534373
Drug: Repeated dose
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dose of SAS
Trial: 2534373
Drug: Double-dose SAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose SAS
Trial: 21720704
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + low-dose IL-2 (CT+IL-2)
Trial: 19695392
Drug: Rifampicin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (600 mg oral dose on day 1)
Trial: 1550909
Drug: Sublingual tablets
RxNorm normalized name: Fentanyl Sublingual Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablets
Trial: 1550909
Drug: Oral sustained-release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sustained-release tablets
Trial: 1550909
Drug: Sustained-release tablets
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release tablets
Trial: 29745307
Drug: Dance program,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance program, twice a week for 10 weeks
Trial: 27865961
Drug: Lifetime major
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifetime major depressive disorder (L-MDD)
Trial: 27865961
Drug: Lifetime generalized
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifetime generalized anxiety disorder (L-GAD)
Trial: 15866630
Drug: Daclizumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (1 mg/kg in two doses; preoperatively and on day 14) combined with steroids, mycophenolate mofetil (initial dose of 2 g/d), and tacrolimus (0.1 mg/kg per day).
Trial: 12063522
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (empty liposomes)
Trial: 9457941
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (Crinone 8%) administered twice daily from day 14, containing 90 mg of micronized progesterone.
Trial: 9457941
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) progesterone, 100 mg administered from cycle days 15 to 27.
Trial: 2234874
Drug: Ibuprofen (26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (26 patients)
Trial: 2234874
Drug: Paracetamol/codeine/caffeine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol/codeine/caffeine combination (Solpadeine) (25 patients)
Trial: 376074
Drug: Ovarian irradiation
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian irradiation (2000 rads in 5 days) plus prednisone, 7.5 mg daily
Trial: 29873278
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavior therapy (iCBT) for chronic tinnitus
Trial: 23160488
Drug: omega‐6 once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega‐6 once daily
Trial: 21736785
Drug: Decaffeinated green
RxNorm normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated green tea extract (DGT; 530 mg containing about 400 mg total catechins/capsule, twice daily)
Trial: 11244517
Drug: Adjunct balloon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct balloon angioplasty
Trial: 9189106
Drug: Teicoplanin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (12 mg/kg intravenously)
Trial: 30624344
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo or alternative treatment during the crossover)
Trial: 28951525
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g mixed eicosapentaenoic acid/docosahexaenoic acid in soft-gel capsules
Trial: 28951525
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g mixed eicosapentaenoic acid/docosahexaenoic acid in Smartfish drinks
Trial: 28951525
Drug: Both omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both omega-3 PUFA formulations
Trial: 26068234
Drug: High-dose Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Vitamin D3 supplementation
Trial: 19650808
Drug: Regional anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional anticoagulation (heparin pre-filter plus post-filter protamine) plus antiaggregation (pre-filter prostacyclin) [Group 1 (G1)]